



# Prediabetes with Hypertension and Dyslipidemia: Are They Triad of Future Cardiovascular Risk?

Venu Gopal Jonnalagadda<sup>1</sup>

Published online: 13 October 2018  
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Dear Editor,

I have read the research proposal “A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS)” by Jhang J. et al., with great interest. The authors presented a clinical trial protocol proposal to compare the effect of pitavastatin and atorvastatin on glucose metabolism in prediabetics with hypertension and dyslipidemia [1]. I would like to request the authors to clarify or elucidate the following point for better understanding of the rationale and design.

Statins are better known for its diabetogenic potential by causing/altering inhibition of  $\beta$ -cell glucose transporters,  $\beta$ -cell apoptosis, pro-inflammatory and oxidative  $\beta$ -cell effects of plasma-derived cholesterol, delayed ATP production, decrease in the secretion of insulin, and decrease in adiponectin levels [2]. Hence, after adding statins to the prediabetics, causes increase in HbA1c levels exponentially; however, the

authors did not mention about the rescue medication used for those sensitive patients [1].

I would be highly obliged for your kind consideration of the abovementioned clarification in your article to understand the effect of pitavastatin and atorvastatin on glucose metabolism in prediabetics with hypertension and dyslipidemia.

## Compliance with Ethical Standards

**Conflict of Interest** None.

## References

1. Zhang J, Shao Y, Liu Y, Tao J. A multi-center, open-label, two-arm parallel group non-inferiority randomized controlled trial evaluating the effect of Pitavastatin, compared to atorvastatin, on glucose metabolism in prediabetics with hypertension and dyslipidemia: rationale and design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS). *Cardiovasc Drugs Ther.* 2018 Sep 5.
2. Jonnalagadda VG, Choudhary K, Matety VK. Statins and new onset of diabetes: which one outweighs risk or benefit? *Postgrad Med.* 2018 Jan;130(1):146.

---

✉ Venu Gopal Jonnalagadda  
gopalvenu63@gmail.com

<sup>1</sup> Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, C/O NETES Institute of Technology & Science, NH-37, Shantipur, Parli Part, Mirza, Assam 781125, India